» Articles » PMID: 17047647

Secondary Dissemination in Children with High-grade Malignant Gliomas and Diffuse Intrinsic Pontine Gliomas

Overview
Journal Br J Cancer
Specialty Oncology
Date 2006 Oct 19
PMID 17047647
Citations 27
Authors
Affiliations
Soon will be listed here.
Abstract

In children, treatment regimen for high-grade gliomas (HGG) and diffuse intrinsic pontine gliomas (DIPG) are generally not stratified according to disease stage. The hypothesis was that secondary disseminating disease (SDD) in children with HGG is related to an even worse outcome. Description of SDD pattern was performed. In total, 270 children with newly diagnosed HGG or DIPG were eligible for retrospective analysis of SDD. Medical and computer records of these patients were reviewed for demographic characteristics, sites of dissemination, prognostic variables. Forty-six (17%) of the 270 patients had developed SDD. The median time to SDD was 8.2 months. The median overall survival (OS) after dissemination was 3.2 months. The SDD was located parenchymal in the supratentorial (34.8%), infratentorial (6.5%), supratentorial and infratentorial (19.6%), spinal (10.9%), spinal and cerebral (6.5%) regions of the CNS, or leptomeningeal (21.7%). For HGG patients, the median OS was shorter among patients with SDD than among patients without SDD (1.02 vs 1.41 years, P=0.0495). In the group of patients with SDD, patients with cerebrospinal fluid dissemination had a worse outcome compared with patients with parenchymal metastases. Summarising, SDD is a negative prognostic factor for patients with HGG outside the pons. Treatment stratification should be considered.

Citing Articles

Bone Morphogenic Proteins in Pediatric Diffuse Midline Gliomas: How to Make New Out of Old?.

Berthelot C, Huchede P, Bertrand-Chapel A, Beuriat P, Leblond P, Castets M Int J Mol Sci. 2024; 25(6).

PMID: 38542334 PMC: 10969837. DOI: 10.3390/ijms25063361.


Advances in Treatment of Diffuse Midline Gliomas.

Cacciotti C, Wright K Curr Neurol Neurosci Rep. 2023; 23(12):849-856.

PMID: 37921944 DOI: 10.1007/s11910-023-01317-8.


Diffuse midline glioma invasion and metastasis rely on cell-autonomous signaling.

Bruschi M, Midjek L, Ajlil Y, Vairy S, Lancien M, Ghermaoui S Neuro Oncol. 2023; 26(3):553-568.

PMID: 37702430 PMC: 10912010. DOI: 10.1093/neuonc/noad161.


Leptomeningeal dissemination in pediatric brain tumors.

Cocito C, Martin B, Giantini-Larsen A, Valcarce-Aspegren M, Souweidane M, Szalontay L Neoplasia. 2023; 39:100898.

PMID: 37011459 PMC: 10124141. DOI: 10.1016/j.neo.2023.100898.


Pediatric diffuse midline glioma H3K27- altered: A complex clinical and biological landscape behind a neatly defined tumor type.

Vallero S, Bertero L, Morana G, Sciortino P, Bertin D, Mussano A Front Oncol. 2023; 12:1082062.

PMID: 36727064 PMC: 9885151. DOI: 10.3389/fonc.2022.1082062.


References
1.
Packer R, Boyett J, Zimmerman R, RORKE L, Kaplan A, Albright A . Hyperfractionated radiation therapy (72 Gy) for children with brain stem gliomas. A Childrens Cancer Group Phase I/II Trial. Cancer. 1993; 72(4):1414-21. DOI: 10.1002/1097-0142(19930815)72:4<1414::aid-cncr2820720442>3.0.co;2-c. View

2.
Grabb P, Albright A, Pang D . Dissemination of supratentorial malignant gliomas via the cerebrospinal fluid in children. Neurosurgery. 1992; 30(1):64-71. DOI: 10.1227/00006123-199201000-00012. View

3.
Wolff J, Molenkamp G, Westphal S, Pietsch T, Gnekow A, Kortmann R . Oral trofosfamide and etoposide in pediatric patients with glioblastoma multiforme. Cancer. 2000; 89(10):2131-7. DOI: 10.1002/1097-0142(20001115)89:10<2131::aid-cncr14>3.0.co;2-j. View

4.
Arita N, Taneda M, Hayakawa T . Leptomeningeal dissemination of malignant gliomas. Incidence, diagnosis and outcome. Acta Neurochir (Wien). 1994; 126(2-4):84-92. DOI: 10.1007/BF01476415. View

5.
Saito R, Kumabe T, Jokura H, Shirane R, Yoshimoto T . Symptomatic spinal dissemination of malignant astrocytoma. J Neurooncol. 2003; 61(3):227-35. DOI: 10.1023/a:1022536828345. View